4.7 Article

Cascaded Multi-view Canonical Correlation (CaMCCo) for Early Diagnosis of Alzheimer's Disease via Fusion of Clinical, Imaging and Omic Features

Journal

SCIENTIFIC REPORTS
Volume 7, Issue -, Pages -

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/s41598-017-03925-0

Keywords

-

Funding

  1. National Cancer Institute of the National Institutes of Health [1U24CA199374-01, R01CA202752-01A1, R01CA208236-01A1, R21CA179327-01, R21CA195152-01]
  2. National Institute of Diabetes and Digestive and Kidney Diseases [R01DK098503-02]
  3. National Center for Research Resources [1 C06 RR12463-01]
  4. DOD Prostate Cancer Synergistic Idea Development Award [PC120857]
  5. DOD Lung Cancer Idea Development New Investigator Award [LC130463]
  6. DOD Prostate Cancer Idea Development Award
  7. DOD Peer Reviewed Cancer Research Program [W81XWH-16-1-0329]
  8. Case Comprehensive Cancer Center Pilot Grant VelaSano Grant from the Cleveland Clinic the Wallace H. Coulter Foundation Program in the Department of Biomedical Engineering at Case Western Reserve University
  9. Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01 AG024904]
  10. DOD ADNI (Department of Defense) [W81XWH-12-2-0012]
  11. National Institute on Aging
  12. National Institute of Biomedical Imaging and Bioengineering
  13. Alzheimer's Association
  14. Alzheimer's Drug Discovery Foundation
  15. Araclon Biotech
  16. BioClinica, Inc.
  17. Biogen Idec Inc.
  18. Bristol-Myers Squibb Company
  19. Eisai Inc.
  20. Elan Pharmaceuticals, Inc.
  21. Eli Lilly and Company
  22. EuroImmun
  23. F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.
  24. Fujirebio
  25. GE Healthcare
  26. IXICO Ltd.
  27. Janssen Alzheimer Immunotherapy Research & Development, LLC
  28. Johnson & Johnson Pharmaceutical Research & Development LLC
  29. Medpace, Inc.
  30. Merck Co., Inc.
  31. Meso Scale Diagnostics, LLC
  32. NeuroRx Research
  33. Neurotrack Technologies
  34. Novartis Pharmaceuticals Corporation
  35. Pfizer Inc.
  36. Piramal Imaging
  37. Servier
  38. Synarc Inc.
  39. Takeda Pharmaceutical Company
  40. Canadian Institutes of Health Research

Ask authors/readers for more resources

The introduction of mild cognitive impairment (MCI) as a diagnostic category adds to the challenges of diagnosing Alzheimer's Disease (AD). No single marker has been proven to accurately categorize patients into their respective diagnostic groups. Thus, previous studies have attempted to develop fused predictors of AD and MCI. These studies have two main limitations. Most do not simultaneously consider all diagnostic categories and provide suboptimal fused representations using the same set of modalities for prediction of all classes. In this work, we present a combined framework, cascaded multiview canonical correlation (CaMCCo), for fusion and cascaded classification that incorporates all diagnostic categories and optimizes classification by selectively combining a subset of modalities at each level of the cascade. CaMCCo is evaluated on a data cohort comprising 149 patients for whom neurophysiological, neuroimaging, proteomic and genomic data were available. Results suggest that fusion of select modalities for each classification task outperforms (mean AUC = 0.92) fusion of all modalities (mean AUC = 0.54) and individual modalities (mean AUC = 0.90, 0.53, 0.71, 0.73, 0.62, 0.68). In addition, CaMCCo outperforms all other multi-class classification methods for MCI prediction (PPV: 0.80 vs. 0.67, 0.63).

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available